A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elective or Urgent Cardiac Surgery
Phase of Trial: Phase IV
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Postoperative infections; Surgical blood loss
- Focus Therapeutic Use
- Acronyms PREFER-CABG
- 01 Nov 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 01 Nov 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 05 Oct 2018 Status changed from not yet recruiting to recruiting.